Cell-Based Assays: World Market Prospects 2012-2022
NEW YORK, March 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Cell-Based Assays: World Market Prospects 2012-2022
http://www.reportlinker.com/p0409089/Cell-Based-Assays-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
Report Details
What does the future hold for cell-based assays in pharma? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions.
Our study analyses products and services for cell-based testing. It covers activities of product developers and pre-clinical contract research organisations.
You discover sales predictions to 2022 at world market, main submarket and national levels. Find potential revenues for products and services.
Also, you receive discussions of many companies in the cell assay industry, seeing their activities and outlooks.
Companies featured include the following:
• BD Biosciences
• Life Technologies
• PerkinElmer
• Beckman Coulter
• Evotec
• GE Healthcare
• Thermo Fisher Scientific
• Covance
• PPD
• Charles River Laboratories
• MD Biosciences.
Looking ahead to 2022, many commercial opportunities exist for cell-based testing. Our report gives you business research and analysis there.
Where are cellular assays heading? Greater need for cellular information earlier in pre-clinical product development stimulates demand for the tests. Our report shows you how their use is increasing in drug discovery and development.
Which developmental processes will benefit most from cell assays? This decade, drug screening and toxicity testing will be important applications for cell-based products and services, our analysis shows.
At present, half of all assays used in pharmaceutical development are cell-based. Miniaturisation and automation are important. We find wide scope for developing the systems and applications from 2012 to 2022, seeing many opportunities.
What are the limitations of cell-based assays? For their potential to be achieved, challenges must be tackled. Systems such as 3D assays will allow for more-accurate simulation of in vivo conditions in cell cultures. Our report explains.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers now in our work.
Revenue forecasts, market shares, developmental trends and discussions
In our report you find revenue forecasting, growth rates and market shares. Also, you have qualitative analyses (SWOT and STEP) and discussion of technologies, existing and in development. You receive 74 tables and charts and two research interviews.
Advantages of Cell-Based Assays: World Market Prospects 2012-2022 for your work
In particular, this study gives you the following knowledge:
• Find potential revenues to 2022 for the world market and submarkets
• See market forecasting to 2022 for US, Japan, EU5, China and India
• Assess leading companies, discovering activities and outlooks
• Review technological developments, assessing trends and prospects
• Investigate competition and opportunities influencing revenues
• Find out what will stimulate and restrain the industry and market
• Analyse pharma R&D spending by stage and find an overall forecast to 2022
• View opinions from our survey, receiving detailed interviews.
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. Without our report, you could miss out on information that your competitors are using.
We analyse developments and prospects in cellular testing, helping you to stay ahead.
Gain business research and analysis for cell-based assays
Our study is for everybody needing industry and market analyses for cell assays. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Cell-Based Assays: World Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
2. An Introduction to Cell-Based Assays
2.1 Drug Discovery and Development
2.1.1 Approaches to Drug Development
2.2 Drug Screening Assays
2.2.1 Animal Models
2.2.2 Biochemical Assays
2.2.3 Uses for Drug Screening Assays
2.2.3.1 Lead Identification
2.2.3.2 Toxicity Testing
2.3 Cell-Based Assays
2.3.1 Assay Format
2.3.2 Assay Detection Technology
2.3.3 Cells Used in a Cell-Based Assay
2.3.3.1 Immortalised Cell Lines
2.3.3.2 Primary Cells
2.3.3.3 Stem Cells
2.3.4 Uses for Cell-Based Assays in Drug Discovery and Development
2.3.4.1 Target Validation
2.3.4.2 Primary Screening
2.3.4.3 Secondary Screening
2.3.4.4 ADME Screening
2.3.4.5 High Throughput Screening
3. The Cell-Based Assays Market 2012-2022
3.1 The Cell-Based Assays Market 2010-2011
3.1.1 The Cell-Based Assays Market by Application, 2010-2011
3.2 The Cell-Based Assays Market Forecast, 2012-2022
3.2.1 The Cell-Based Assays Market as a Share of R&D Spending, 2012-2022
3.3 Outsourced Cell-Based Assay Services Submarket 2010-2011
3.3.1 Outsourced Cell-Based Assay Services Submarket: Revenue Forecast 2012-2022
3.4 Cell-Based Assay Products Submarket 2010-2011
3.4.1 Cell-Based Assay Product Categories
3.4.1.1 Equipment
3.4.1.2 Disposables
3.4.1.3 Consumables
3.4.2 Cell-Based Assay Products Submarket: Revenue Forecast 2012-2022
4. Leading National Cell-Based Assay Markets 2012-2022
4.1 Leading National Markets for Cell-Based Assays 2010-2011
4.2 Leading National Markets: Revenue Forecasts 2012-2022
4.3 The US: Revenues 2012-2022
4.4 Japan: Revenues 2012-2022
4.5 Europe
4.5.1 The European Market: Revenues 2010-2011
4.5.2 The European Market: Revenue Forecasts 2012-2022
4.6 Cell-Based Assays in the Leading Emerging Countries
4.6.1 China: Revenues 2012-2022
4.6.2 India: Revenues 2012-2022
5. Leading Companies in the Cell-Based Assays Market in 2011
5.1 Cell-Based Assay Service Companies
5.1.1 Global CROs
5.1.1.1 Covance
5.1.1.2 PPD
5.1.1.3 Charles River Laboratories
5.1.2 Specialist CROs and Service Companies
5.1.2.1 FluoFarma
5.1.2.2 Marin Biologic Laboratories
5.1.2.3 MD Biosciences
5.2 Cell-Based Assay Product Suppliers
5.3 BD Biosciences
5.3.1 BD Acquires Accuri Cytometers
5.4 Beckman Coulter
5.5 DiscoveRx
5.5.1 DiscoveRx and GPCRs
5.6 EMD Millipore
5.6.1 Expanding in Toxicity Research
5.7 Evotec
5.8 GE Healthcare
5.8.1 GE Healthcare and Stem Cells
5.9 Life Technologies (Invitrogen)
5.10 Molecular Devices
5.11 PerkinElmer
5.11.1 High Content Screening
5.11.2 Caliper Life Sciences
5.11.2.1 Caliper Discovery Alliances and Services
5.12 Promega
5.12.1 Multiplexing Toxicity Testing Tools
5.12.2 Stem Cells
5.13 Sigma-Aldrich
5.13.1 Sigma's ADME-Tox Services
5.14 Thermo Fisher Scientific
5.15 TTP LabTech
5.15.1 Chemotaxis Research
6. Cell-Based Assays: Industry Trends 2012-2022
6.1 Strengths and Weaknesses in the Cell-Based Assays Market 2011
6.1.1 Cell-Based Assays are More Biologically Relevant
6.1.2 Two-Dimensional Cell Assays Have Limitations
6.1.3 An Alternative to Animal Testing
6.2 Opportunities and Threats in the Cell-Based Assays Market 2012-2022
6.2.1 Social Developments
6.2.2 Technological Advances
6.2.3 Economic Pressures
6.2.4 Political Issues
6.3 Stem Cells
6.3.1 The Need for Stem Cells in Cell-Based Assays
6.3.2 Stem Cells Hold Significant Potential
6.3.3 Induced Pluripotent Stem Cells: An Uncontroversial and Abundant Source
6.3.4 Companies Providing Stem Cell Products for the Cell-Based Assay Market
6.3.4.1 Axiogenesis
6.3.4.2 Cellular Dynamics International
6.3.4.3 MultiCell Technologies
6.3.4.4 Stem Cell Innovations
6.4 G-Protein-Coupled Receptors (GPCRs): A Common Drug Discovery Target
6.4.1 The Role of Cell-Based Assays
6.4.2 Allosteric GPCRs Provide a New Approach
6.5 Miniaturisation and Automation
6.5.1 The Demand for Miniaturisation
6.5.2 Microfluidics
6.5.2.1 The Future Potential of Microfluidics
6.5.3 The Trend Towards Automation
6.5.4 Multiplexing: Making Cell-Based Assays More Efficient
6.6 Detection in Cell-Based Assays
6.6.1 High Content Screening (HCS)
6.6.1.1 Future Developments in HCS
6.6.2 Label-Free Technology
6.6.2.1 The Potential of Label-Free Assays
6.6.2.2 CellKey (Molecular Devices)
6.6.2.3 Epic (Corning)
6.6.2.4 xCELLigence (Roche Applied Science/ACEA Biosciences)
6.7 Three-Dimensional Cell-Based Assays: Closer to the True Cellular Environment
6.7.1 Challenges in 3D Cell Culture
6.8 Toxicity Testing: A Key Market for Cell-Based Assays
6.8.1 Alternative Approaches
6.8.2 Restraints on Development
6.8.3 Apredica
6.9 Outsourcing Cell-Based Assays
6.9.1 Why Outsource?
6.10 Growing Interest in Biologics and Biosimilars: A Trend from the Pharmaceutical Industry
7. Research Interviews
7.1 Dr Jan Ehlert, Head of Cellular Drug Discovery, ProQinase
7.1.1 ProQinase
7.1.2 Challenge Facing Cell-Based Assay Use
7.1.3 The Benefits of Using a CRO
7.1.4 Future Advances Set to Benefit Cell-Based Assay Development
7.2 Rob Chaney, General Manager and COO, ReachBio
7.2.1 ReachBio
7.2.2 Cell-Based Assays and Their Application in the Biopharmaceutical Industry
7.2.3 Drivers and Restraints for the Cell-Based Assays Market
7.2.4 The Use of Stem Cells in Cell-Based Assays
7.2.5 The Latest Trends in the Cell-Based Assays Market
8. Conclusions from Our Study
8.1 The Cell-Based Assays Market in 2010-2011
8.2 Outlook for the Cell-Based Assays Market 2012-2022
8.2.1 Regional Outlook for the Market 2012-2022
8.3 Future Opportunities for Cell-Based Assay Developers
8.4 Challenges to be Overcome
List of Tables
Table 2.1 Key Parameters Required in Drug Discovery and Development
Table 2.2 Selected Label-Free Detection Technologies Used for Cell-Based Assays
Table 3.1 Cell-Based Assays Market by Sector, 2010-2011
Table 3.2 Cell-Based Assays Market by Application, 2010
Table 3.3 Cell-Based Assays Market: Overall World Market and Submarket Revenue Forecasts, 2010-2022
Table 3.4 Cell-Based Assays Market: Drivers and Restraints, 2012-2022
Table 3.5 Pharmaceutical R&D: Global Spending Forecast, 2010-2022
Table 3.6 Pharmaceutical R&D Spending by Developmental Stage, 2010
Table 3.7 Drug Discovery Outsourcing: Drivers, 2011
Table 3.8 Cell-Based Assay Services Submarket: Revenue Forecast, 2010-2022
Table 3.9 Cell-Based Assays: Submarket Shares, 2010-2022
Table 3.10 Commercially-Available Robotic Systems for Liquid Handling and Cell Culture, 2011
Table 3.11 Cell-Based Assay Products Submarket: Revenue Forecast, 2010-2022
Table 4.1 Cell-Based Assays Market by Region, 2010
Table 4.2 Developed Cell-Based Assays Markets: Drivers and Restraints, 2012-2022
Table 4.3 Emerging Cell-Based Assays Markets: Drivers and Restraints, 2012-2022
Table 4.4 Cell-Based Assays Market: Revenue Forecasts by Region, 2010-2022
Table 4.5 Cell-Based Assays Market: Seven Major Markets versus the Rest of the World, 2010, 2016 & 2022
Table 4.6 US Cell-Based Assays Market: Revenue Forecast, 2010-2022
Table 4.7 Japanese Cell-Based Assays Market: Revenue Forecast, 2010-2022
Table 4.8 European Cell-Based Assays Market by Country, 2010
Table 4.9 European Cell-Based Assays Market: Revenue Forecasts for Leading Countries, 2010-2022
Table 4.10 Chinese Cell-Based Assays Market: Revenue Forecast, 2010-2022
Table 4.11 Indian Cell-Based Assays Market: Revenue Forecast, 2010-2022
Table 5.1 Covance: Revenue by Sector, 2008-2010
Table 5.2 BD Biosciences: Revenue by Sector, 2009-2010
Table 5.3 Evotec: Selected Discovery and Development Alliances, 2009-2011
Table 5.4 Life Technologies: Cell-Based Technology Platforms, 2011
Table 5.5 Danaher: Life Science Subsidiaries, 2011
Table 5.6 Thermo Fisher Scientific: Revenue by Sector, 2009-2010
Table 5.7 TTP LabTech: Selected Cell-Based Assay Relevant Products, 2011
Table 6.1 Cell-Based Assays Market: Strength and Weaknesses, 2011
Table 6.2 Cell-Based Assays Market: Opportunities and Threats, 2012-2022
Table 6.3 Pharmaceutical Outsourcing Market by Sector, 2010-2011
Table 6.4 Selected Companies Offering Stem Cell Products for Drug Development, 2011
Table 6.5 Reporter Gene Technology for Cell-Based Assays: Benefits and Weaknesses, 2011
Table 6.6 Selected Companies Offering Label-Free Assay Systems, 2011
Table 6.7 World Biologics Market: Revenues, 2010 & 2016
Table 8.1 Cell-Based Assays Market: Overall Revenue Forecast and Submarket Shares, 2010-2022
Table 8.2 Cell-Based Assays Market: Overall Revenue Forecast and Regional Market Shares, 2010-2022
List of Figures
Figure 1.1 Pharmaceutical R&D Expenditure by Developmental Stage, 2009
Figure 2.1 Stages of Pre-Clinical Drug Development
Figure 2.2 High Profile Toxicity-Related Withdrawals, 1991-2010
Figure 3.1 Cell-Based Assays Market by Sector, 2010 & 2011
Figure 3.2 Cell-Based Assays Market by Application, 2010
Figure 3.3 Cell-Based Assays Market: Overall World Revenue Forecast, 2010-2022
Figure 3.4 Pharmaceutical R&D: Global Spending Forecast, 2010-2022
Figure 3.5 Pharmaceutical R&D Spending by Developmental Stage, 2010
Figure 3.6 Pharmaceutical R&D Spending versus Cell-Based Assay Spending, 2016
Figure 3.7 Pharmaceutical R&D Spending versus Cell-Based Assay Spending, 2022
Figure 3.8 Cell-Based Assay Services Submarket: Revenue Forecast, 2010-2022
Figure 3.9 Cell-Based Assays: Submarket Shares, 2016
Figure 3.10 Cell-Based Assays: Submarket Shares, 2022
Figure 3.11 Cell-Based Assay Products Market Model, 2011
Figure 3.12 Cell-Based Assay Products Submarket: Revenue Forecast, 2010-2022
Figure 4.1 Cell-Based Assays Market by Region, 2010
Figure 4.2 Cell-Based Assays Market: Seven Major Markets versus the Rest of the World, 2016
Figure 4.3 Cell-Based Assays Market: Seven Major Markets versus the Rest of the World, 2022
Figure 4.4 US Cell-Based Assays Market: Revenue Forecast, 2010-2022
Figure 4.5 Japanese Cell-Based Assays Market: Revenue Forecast, 2010-2022
Figure 4.6 European Cell-Based Assays Market by Leading Country, 2010
Figure 4.7 European Cell-Based Assays Market: Revenue Forecast, 2010-2022
Figure 4.8 UK and German Cell-Based Assays Markets: Revenue Forecasts, 2010-2022
Figure 4.9 French, Italian and Spanish Cell-Based Assays Markets: Revenue Forecasts, 2010-2022
Figure 4.10 European Cell-Based Assays Market Shares, 2010, 2016 & 2022
Figure 4.11 Chinese Cell-Based Assays Market: Revenue Forecast, 2010-2022
Figure 4.12 Indian Cell-Based Assays Market: Revenue Forecast, 2010-2022
Figure 5.1 Covance: Revenue by Sector, 2008, 2009 & 2010
Figure 5.2 BD Biosciences: Revenue by Sector, 2009-2010
Figure 5.3 Thermo Fisher Scientific Revenue by Sector, 2009-2010
Figure 6.1 Pharmaceutical Outsourcing Market by Sector, 2010-2011
Figure 6.2 World Biologics Market: Revenues, 2010 & 2016
Figure 8.1 Cell-Based Assays Market: Overall Revenue Forecast and Submarket Shares, 2010-2022
Figure 8.2 Cell-Based Assays Market: Overall Revenue Forecast and Regional Market Shares, 2010-2022
Companies Listed
AB SCIEX (a subsidiary of Danaher)
Accuri Cytometers (now part of BD)
ACEA Biosciences
Active Biotech
Advinus Therapeutics
Agennix
Agilent Automation Solutions
APEIRON Biologics
Applied BioPhysics
Apredica (now part of Cyprotex)
AstraZeneca
ATCC (formerly the American Type Culture Collection) [US]
Aurigene Discovery Technologies (a subsidiary of Dr Reddy's Laboratories)
Axiogenesis
BD Biosciences (a division of Becton, Dickinson & Co - BD)
Beckman Coulter (now part of Danaher)
Becton, Dickinson & Co.
BellBrook Labs
Bionas
Biopredic International
BioTek Instruments
BioTime
Boehringer Ingelheim
Boehringer Mannheim
Caliper Discovery Alliances and Services (CDAS, a subsidiary of Caliper Life Sciences)
Caliper Life Sciences (now part of PerkinElmer)
CellCyte Genetics
Cellomics (now part of Thermo Fisher Scientific)
Cellular Dynamics International
Cellumen
Charles River Laboratories
ChemBridge
Codex BioSolutions
Compugen
Corning Life Sciences
Cosmo Bio
Covance
Cubist Pharmaceuticals
Cyprotex
Cytogration
Danaher
Digilab
DiscoveRx
Dr. Reddy's Laboratories
EMD Millipore
Epistem
Eppendorf
European Collection of Cell Culture (ECACC)
European Commission (EC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European ScreeningPort
Evotec
Evotec Technologies (a subsidiary of PerkinElmer)
FluoFarma
GE Healthcare (a division of General Electric)
Genentech (part of Roche)
General Electric (GE)
Genospectra
Geron
GSK
Hamilton Robotics
Harvard NeuroDiscovery Center
Harvard University
HD Biosciences
HighRes Biosolutions
Hudson Robotics
IonGate
Jubilant Biosys (a subsidiary of Jubilant Life Sciences)
Jubilant Life Sciences
Labcyte
Leica Microsystems (a subsidiary of Danaher)
Life Technologies
Lonza
Marin Biologic Laboratories
Matrical Bioscience
Maxim Biotech
MD Biosciences
MDS Analytical Technologies (now part of Danaher)
MedImmune
Merck KGaA
Midas Mediscience
Ministry of Education, Culture, Sports, Science and Technology [Japan]
Molecular Devices (a subsidiary of Danaher)
MRC (Medical Research Council) Technology
MultiCell Technologies
Novartis
NovaScreen Biosciences (part of Caliper Life Sciences)
Parexel International
PerkinElmer
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
PharmaGap
PPD
Promega
ProQinase
Proteome Sciences R&D
PsychoGenics
Puracyp
Q3DM (part of Beckman Coulter)
Quintiles
Radiometer (a subsidiary of Danaher)
ReachBio
Roche
Roche Applied Science (a division of Roche)
Seahorse Bioscience
Sentigen Holding (part of Life Technologies)
Shionogi
Sigma-Aldrich
SRU Biosystems
Stem Cell Innovations
Stemgent
SymCel
TAP Biosystems
Tata Group
Tecan
Thermo Fisher Scientific
TTP LabTech
Tumour Biology Center Freiburg
UCB
University of Kyoto
University of Michigan
University of Tübingen
Veritas
Vitro Biopharma
World Trade Organizatihttp://www.reportlinker.comon (WTO)
Xenogen Biosciences (formerly part of Caliper Life Sciences, acquired by Taconic in 2009)
To order this report:
In Vitro Diagnostic Industry: Cell-Based Assays: World Market Prospects 2012-2022
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article